🚀 VC round data is live in beta, check it out!

d1000 Valuation Multiples

Discover revenue and EBITDA valuation multiples for d1000 and similar public comparables like PetMeds, Talea Group, MARX Biotech, BlueMTec and more.

Start Free TrialSee companies similar to d1000

d1000 Overview

About d1000

D1000 Varejo Farma Participacoes SA invests in national or foreign pharmaceutical retail companies.

Founded

2010

HQ

Brazil

Employees

N/A

Sectors

Pharmacies

Financials (FY)

Revenue: $411M
EBITDA: $34M

EV

$152M

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

d1000 Financials

d1000 reported last fiscal year revenue of $411M and EBITDA of $34M.

In the same fiscal year, d1000 generated $126M in gross profit, $34M in EBITDA, and $5M in net income.

d1000 P&L

In the most recent fiscal year, d1000 reported revenue of $411M and EBITDA of $34M.

d1000 expects next 12-month revenue of XXX and NTM EBITDA of XXX

See d1000 forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue—XXX$411MXXXXXXXXX
Gross Profit—XXX$126MXXXXXXXXX
Gross Margin—XXX31%XXXXXXXXX
EBITDA—XXX$34MXXXXXXXXX
EBITDA Margin—XXX8%XXXXXXXXX
EBIT Margin—XXX3%XXXXXXXXX
Net Profit—XXX$5MXXXXXXXXX
Net Margin—XXX1%XXXXXXXXX

Financial data powered by Morningstar, Inc.

d1000 Stock Performance

d1000 has current market cap of $72M, and enterprise value of $152M.

Market Cap Evolution

d1000's stock price is $1.42.

See d1000 trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$152M$72M(0.6%)XXXXXXXXX$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

d1000 Valuation Multiples

d1000 trades at 0.4x EV/Revenue multiple, and 4.4x EV/EBITDA.

See valuation multiples for d1000 and 15K+ public comps

d1000 Financial Valuation Multiples

As of March 7, 2026, d1000 has market cap of $72M and EV of $152M.

Equity research analysts estimate d1000's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

d1000 has a P/E ratio of 14.7x.

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$72MXXX$72MXXXXXXXXX
EV (current)$152MXXX$152MXXXXXXXXX
EV/Revenue—XXX0.4xXXXXXXXXX
EV/EBITDA—XXX4.4xXXXXXXXXX
EV/EBIT—XXX12.7xXXXXXXXXX
EV/Gross Profit—XXX1.2xXXXXXXXXX
P/E—XXX14.7xXXXXXXXXX
EV/FCF—XXX9.8xXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified d1000 Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

d1000 Margins & Growth Rates

d1000's revenue in the last fiscal year grew by 24%.

See operational valuation multiples for d1000 and other 15K+ public comps

d1000 Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue Growth—XXX24%XXXXXXXXX
EBITDA Margin—XXX8%XXXXXXXXX
EBITDA Growth—XXX13%XXXXXXXXX
S&M Expenses to Revenue—XXX24%XXXXXXXXX
G&A Expenses to Revenue—XXX4%XXXXXXXXX
Opex to Revenue—XXX28%XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

d1000 Public Comps

See public comps and valuation multiples for other Pharmacies comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
PetMedsXXXXXXXXXXXXXXXXXX
Talea GroupXXXXXXXXXXXXXXXXXX
MARX BiotechXXXXXXXXXXXXXXXXXX
BlueMTecXXXXXXXXXXXXXXXXXX
SC RopharmaXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

d1000 M&A Activity

d1000 acquired XXX companies to date.

Last acquisition by d1000 was on XXXXXXXX, XXXXX. d1000 acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by d1000

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

d1000 Investment Activity

d1000 invested in XXX companies to date.

d1000 made its latest investment on XXXXXXXX, XXXXX. d1000 invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by d1000

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About d1000

When was d1000 founded?d1000 was founded in 2010.
Where is d1000 headquartered?d1000 is headquartered in Brazil.
Is d1000 publicly listed?Yes, d1000 is a public company listed on B3.
What is the stock symbol of d1000?d1000 trades under DMVF3 ticker.
When did d1000 go public?d1000 went public in 2020.
Who are competitors of d1000?d1000 main competitors are PetMeds, Talea Group, MARX Biotech, BlueMTec.
What is the current market cap of d1000?d1000's current market cap is $72M.
What is the current revenue of d1000?d1000's last fiscal year revenue is $411M.
What is the current EV/Revenue multiple of d1000?Current revenue multiple of d1000 is 0.4x.
Is d1000 profitable?No, d1000 is not profitable.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial